Beryl Drugs Limited (BOM:524606)
India · Delayed Price · Currency is INR 23.00
0.00 (0.00%)
At close: Aug 18, 2026
Beryl Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 215.51 | 188.2 | 211.46 | 267.3 | 268.71 | 146.04 | |
Revenue Growth | 9.44% | -11.00% | -20.89% | -0.53% | 84.00% | 3.62% |
Cost of Revenue | 121.71 | 97.67 | 112.22 | 135.62 | 148.43 | 85.66 |
Gross Profit | 93.8 | 90.54 | 99.24 | 131.68 | 120.28 | 60.37 |
Selling, General & Admin | 26.26 | 25.29 | 22.58 | 19.69 | 17.3 | 13.46 |
Other Operating Expenses | 42.31 | 40.99 | 48.05 | 84.68 | 80.64 | 41.4 |
Operating Expenses | 82.86 | 81.21 | 85.47 | 117.24 | 106.18 | 65.72 |
Operating Income | 10.94 | 9.32 | 13.77 | 14.44 | 14.1 | -5.35 |
Interest Expense | -3.05 | -3.44 | -5.19 | -4.48 | -4.18 | -4.2 |
Interest & Investment Income | - | - | 0.19 | 0.21 | 0.12 | 0.14 |
Other Non Operating Income (Expenses) | - | - | -0.12 | -0.18 | -0.2 | 0 |
EBT Excluding Unusual Items | 7.88 | 5.88 | 8.66 | 9.99 | 9.84 | -9.41 |
Gain (Loss) on Sale of Assets | - | - | - | 0.11 | - | - |
Other Unusual Items | - | - | - | - | - | -0.09 |
Pretax Income | 7.88 | 5.88 | 8.66 | 10.1 | 9.84 | -9.5 |
Income Tax Expense | 1.64 | 1.63 | 2.87 | 2.41 | 2.18 | -2.91 |
Net Income | 6.25 | 4.25 | 5.79 | 7.69 | 7.66 | -6.59 |
Net Income to Common | 6.25 | 4.25 | 5.79 | 7.69 | 7.66 | -6.59 |
Net Income Growth | 169.06% | -26.61% | -24.69% | 0.34% | - | - |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Change | -2.80% | -0.29% | - | - | - | -0.01% |
EPS (Basic) | 1.25 | 0.84 | 1.14 | 1.52 | 1.51 | -1.30 |
EPS (Diluted) | 1.25 | 0.84 | 1.14 | 1.52 | 1.51 | -1.30 |
EPS Growth | 176.82% | -26.32% | -24.78% | 0.36% | - | - |
Free Cash Flow | - | -1.75 | 4.52 | -5.31 | 8.28 | -8.84 |
Free Cash Flow Per Share | - | -0.34 | 0.89 | -1.05 | 1.63 | -1.74 |
Gross Margin | 43.52% | 48.10% | 46.93% | 49.26% | 44.76% | 41.34% |
Operating Margin | 5.07% | 4.95% | 6.51% | 5.40% | 5.25% | -3.66% |
Profit Margin | 2.90% | 2.26% | 2.74% | 2.88% | 2.85% | -4.51% |
Free Cash Flow Margin | - | -0.93% | 2.14% | -1.99% | 3.08% | -6.05% |
EBITDA | 26.49 | 24.26 | 26.23 | 26.44 | 22.25 | 5.52 |
EBITDA Margin | 12.29% | 12.89% | 12.40% | 9.89% | 8.28% | 3.78% |
D&A For EBITDA | 15.55 | 14.93 | 12.46 | 12 | 8.14 | 10.87 |
EBIT | 10.94 | 9.32 | 13.77 | 14.44 | 14.1 | -5.35 |
EBIT Margin | 5.07% | 4.95% | 6.51% | 5.40% | 5.25% | -3.66% |
Effective Tax Rate | 20.76% | 27.76% | 33.14% | 23.87% | 22.14% | - |
Revenue as Reported | 220.41 | 193.1 | 225.55 | 271.25 | 271.4 | 147.69 |
Advertising Expenses | - | - | 0.16 | 0.12 | 0.17 | 0.13 |